Volume 73, Issue 6, Pages 319-324 (June 2010)

7 of 13

ABSTRACT

ABSTRACT + REFS

FULL-TEXT PDF (200 KB)

Screening for Anti-lipase Properties of 37 Traditional Chinese Medicinal Herbs

Received 12 September 2009; accepted 29 April 2010.

Background

To find new, crude anti-obesity drugs from natural sources through the inhibition of adsorption of dietary lipids, in vitro porcine pancreatic lipase (PPL; triacylglycerol lipase, EC 3.1.1.3) inhibitory tests were carried out on selected plants with weight-reducing or related potential, used in Chinese traditional medicine.

Methods

The methanolic extracts of 37 traditional Chinese herbal medicines of different families were assayed for their in vitro activity against PPL by using spectrophotometry with 2,4-dinitrophenyl butyrate as a synthetic substrate. Coexistent phytochemicals, or those present in high levels, in the 3 most promising Chinese herbs were tested for their anti-lipase activity.

Results

Extracts from 2 herbs, Prunella vulgaris L. (Labiatae) and Rheum palmatum L. (Polygonaceae), at a concentration of 200 mg/mL, significantly inhibited PPL—by 74.7% and 53.8%, respectively. Quercetin exhibited better activity (27.4%) than all the other phytochemicals at a final concentration of 25 mg/mL in the assay system, followed by luteolin, with an activity of 17.3%.

Conclusion

The results support the view that herbs represent a rich source of anti-lipase compounds. The screening of the methanolic extracts of 37 Chinese medicinal plants in vitro led to the identification of several extracts with potential activity against PPL, in particular, P. vulgaris and R. palmatum. We also found that several monomeric chemicals in these herbs exhibited good or moderate activity against PPL. To the best of our knowledge, these traditional Chinese herbal medicines or phytochemicals have not been previously screened for their lipase inhibitory activity.

Key Words: anti-lipase activity , anti-obesity agents , Chinese herbal drugs , Prunella vulgaris L. , Rheum palmatum L.

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

1. 1 Kopelman PG . Obesity as a medical problem . Nature . 2000;404:635–643 . MEDLINE

2. 2 Jebb S . Obesity: causes and consequences . Womens Health Med . 2004;1:38–41 .

3. 3 Finer N . Medical consequences of obesity . Medicine . 2006;34:510–514 .

4. 4 Hedley AA , Ogden CL , Johnson CL , Carroll MD , Curtin LR , Flegal KM . Prevalence of overweight and obesity among US children, adolescents, and adults. 1999–2002 . JAMA . 2004;291:2847–2850 . CrossRef

5. 5 Mokdad AH , Bowman BA , Ford ES , Vinicor F , Marks JS , Koplan JP . The continuing epidemics of obesity and diabetes in the United States . JAMA . 2001;286:1195–2000 . MEDLINE | CrossRef

6. 6 Styne DM . Childhood and adolescent obesity: prevalence and significance . Pediatr Clin North Am . 2001;48:823–854 . Abstract | Full Text | Full-Text PDF (2163 KB) | CrossRef

7. 7 Glazer G . Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety . Arch Intern Med . 2001;161:1814–1824 . MEDLINE | CrossRef

8. 8 Bray GA . Medical therapy for obesity: current status and future hopes . Med Clin North Am . 2007;91:1225–1253 . Abstract | Full Text | Full-Text PDF (346 KB) | CrossRef

9. 9 Bray GA , Tartaglia LA . Medicinal strategies in the treatment of obesity . Nature . 2000;404:672–677 . MEDLINE

10. 10 Cheetham SC , Jackson HC , Vickers SP , Dickinson K , Jones RB , Heal DJ . Novel targets for the treatment of obesity: a review of progress . Drug Discov Today Ther Strateg . 2004;1:227–235 .

11. 11 Birari RB , Bhutani KK . Pancreatic lipase inhibitors from natural sources: unexplored potential . Drug Discov Today . 2007;12:879–889 . CrossRef

12. 12 Mukherjee M . Human digestive and metabolic lipases: a brief review . J Mol Catal B Enzym . 2003;22:369–376 .

13. 13 Thomson AB , De Pover A , Keelan M , Jarocka-Cyrta E , Clandinin MT . Inhibition of lipid absorption as an approach to the treatment of obesity . Meth Enzymol . 1997;286:3–41 .

14. 14 Shi Y , Burn P . Lipid metabolic enzymes: emerging drug targets for the treatment of obesity . Nat Rev Drug Discov . 2004;3:695–710 . MEDLINE

15. 15 Weigle DS . Pharmacological therapy of obesity: past, present, and future . J Clin Endocrinol Metab . 2003;88:2462–2469 . CrossRef

16. 16 Won SR, Kim SK, Kim YM, Lee PH, Ryu JH, Kim JW, et al. Licochalcone A: a lipase inhibitor from the roots of Glycyrrhiza uralensis . Food Res Intern . 2007;40:1046–1050 .

17. 17 Zhao HL , Kim YS . Determination of the kinetic properties of platycodin D for the inhibition of pancreatic lipase using a 1,2-diglyceride-based colorimetric assay . Arch Pharm Res . 2004;27:1048–1052 . MEDLINE | CrossRef

18. 18 Kwon CS, Sohn HY, Kim SH, Kim JH, Son KH, Lee JS, et al Anti-obesity effects of Dioscorea nipponica Makino with lipase inhibitory activity in rodents . Biosci Biotechnol Biochem . 2003;67:1451–1456 . MEDLINE

19. 19 Ono Y , Hattori E , Fukaya Y , Imai S , Ohizumi Y . Anti-obesity effect of Nelumbo ucifera leaves extract in mice and rats . J Ethnopharmacol . 2006;106:238–244 . MEDLINE | CrossRef

20. 20 Mosmuller EWJ , Van Heemst JDH , Van Delden CJ , Franssen MCR , Engbersen JFJ . A new spectrophotometric method for the detection of lipase activity using 2,4-dinitrophenyl butyrate as a substrate . Biocatal Biotransformation . 1992;5:279–287 .

21. 21 Gargouri Y , Ransac S , Verger R . Covalent inhibition of digestive lipases: an in vitro study . Biochim Biophys Acta . 1997;1344:6–37 . MEDLINE

22. 22 Sharma N , Sharma VK , Seo SY . Screening of some medicinal plants for anti-lipase activity . J Ethnopharmacol . 2005;97:453–456 . MEDLINE | CrossRef

23. 23 Zheng J , He J , Ji B , Li Y , Zhang X . Antihyperglycemic activity of Prunella vulgaris L. in streptozotocin-induced diabetic mice . Asia Pac J Clin Nutr . 2007;16(Suppl):427–431 .

24. 24 Xie WD, Xing DM, Zhao YN, Su H, Meng Z, Chen YY, et al. A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit . Eur J Pharmacol . 2005;510:113–120 . MEDLINE | CrossRef

25. 25 Zhang CB, Teng L, Shi Y, Jin JH, Xue YF, Shang KG, et al. Effect of emodin on proliferation and differentiation of 3T3-L1 preadipocyte and FAS activity . Chin Med J . 2002;115:1035–1038 .

26. 26 Yang Y , Shang W , Zhou L , Jiang B , Jin H , Chen M . Emodin with PPARgamma ligand-binding activity promotes adipocyte differentiation and increases glucose uptake in 3T3-Ll cells . Biochem Biophys Res . 2007;353:225–230 .

27. 27 Xing WW , Wu JZ , Jia M , Du J , Zhang H , Qin LP . Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits . Biomed Pharmacother . 2009;63:457–462 . CrossRef

28. 28 Du J, Sun LN, Xing WW, Huang BK, Jia M, Wu JZ, et al Lipid-lowering effects of polydatin from Polygonum cuspi-datum in hyperlipidemic hamsters . Phytomedicine . 2009;16:652–658 . Abstract | Full Text | Full-Text PDF (282 KB) | CrossRef

29. 29 Liu J . Pharmacology of oleanolic acid and ursolic acid . J Ethnopharmacol . 1995;49:57–68 . MEDLINE | CrossRef

a Research Centre for Natural Medicinal Chemistry, College of Science, Yangling, Shaanxi, China

b College of Life Sciences, Northwest Agriculture and Forestry University, Yangling, Shaanxi, China

c College of Animal Science and Technology, Northwest Agriculture and Forestry University, Yangling, Shaanxi, China

Correspondence to: Dr Jin-Ming Gao, Research Centre for Natural Medicinal Chemistry, College of Science, Northwest Agriculture and Forestry University, Yangling 712100, Shaanxi, China

PII: S1726-4901(10)70068-X

doi:10.1016/S1726-4901(10)70068-X

7 of 13